Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
12-valent pneumococcal conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- SK bioscience
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 12-valent pneumococcal conjugate vaccine is a vaccine designed to protect against pneumococcal diseases caused by *Streptococcus pneumoniae* in infants and young children. It contains purified capsular polysaccharides from 12 specific pneumococcal serotypes (1, 4, 5, 6B, 7F, 9V, 14, 23F, 19F, 18C, 6A, and 19A) conjugated to various carrier proteins, including non-typeable *Haemophilus influenzae* protein D, tetanus toxoid (TD), diphtheria toxoid (TT), and CRM197. The vaccine aims to induce an immune response to prevent invasive pneumococcal disease. It is being evaluated for immunologic non-inferiority compared to existing 10-valent and 13-valent vaccines and has been developed by companies such as SK bioscience and Bio-Manguinhos/Fiocruz.
- Other names
- 12Pn-PD-DiT-CRM
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on 12-valent pneumococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 12-valent pneumococcal conjugate vaccine.